Literature DB >> 25481750

The T687G SNP in a P-glycoprotein gene of Fasciola hepatica is not associated with resistance to triclabendazole in two resistant Australian populations.

Timothy P Elliott1, Terry W Spithill2.   

Abstract

Triclabendazole (TCBZ) is widely used for control of Fasciola hepatica (liver fluke) in animals and humans and resistance to this drug is now widespread. However, the mechanism of resistance to TCBZ is not known. A T687G single nucleotide polymorphism (SNP) in a P-glycoprotein gene was proposed as a molecular marker for TCBZ resistance in F. hepatica (Wilkinson et al., 2012). We analyzed this Pgp gene from TCBZ-susceptible and TCBZ-resistant populations from Australia to determine if the SNP was a marker for TCBZ resistance. From the 21 parasites studied we observed 27 individual haplotypes in the Pgp sequences which comprised seven haplotypic groups (A-G), with haplotypes A and B representing 81% of the total observed. The T687G SNP was not observed in either of the resistant or susceptible populations. We conclude that the T687G SNP in this Pgp gene is not associated with TCBZ resistance in these Australian F. hepatica populations and therefore unlikely to be a universal molecular marker for TCBZ resistance.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Drug resistance; Fasciola hepatica; P-glycoprotein; SNP; Triclabendazole

Mesh:

Substances:

Year:  2014        PMID: 25481750     DOI: 10.1016/j.molbiopara.2014.11.006

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  6 in total

1.  The Differences in the Susceptibility Patterns to Triclabendazole Sulfoxide in Field Isolates of Fasciola hepatica Are Associated with Geographic, Seasonal, and Morphometric Variations.

Authors:  Martha V Fernandez-Baca; Cristian Hoban; Rodrigo A Ore; Pedro Ortiz; Young-Jun Choi; César Murga-Moreno; Makedonka Mitreva; Miguel M Cabada
Journal:  Pathogens       Date:  2022-05-28

2.  Clonal amplification of Fasciola hepatica in Galba truncatula: within and between isolate variation of triclabendazole-susceptible and -resistant clones.

Authors:  Jane E Hodgkinson; Krystyna Cwiklinski; Nicola Beesley; Catherine Hartley; Katherine Allen; Diana J L Williams
Journal:  Parasit Vectors       Date:  2018-06-26       Impact factor: 3.876

3.  Evaluation of nitazoxanide treatment following triclabendazole failure in an outbreak of human fascioliasis in Upper Egypt.

Authors:  Haidi Karam-Allah Ramadan; Waleed Attia Hassan; Nahed Ahmed Elossily; Alzahraa Abdelraouf Ahmad; Adnan Ahmed Mohamed; Alaa Soliman Abd-Elkader; Eman M Nagiub Abdelsalam; Hani M J Khojah
Journal:  PLoS Negl Trop Dis       Date:  2019-09-25

4.  Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test.

Authors:  Adam Novobilský; Natalia Amaya Solis; Moa Skarin; Johan Höglund
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-06-26       Impact factor: 4.077

5.  Can P-glycoprotein and β-tubulin polymorphisms be used as genetic markers of resistance in Dirofilaria immitis from Rio de Janeiro, Brazil?

Authors:  Liliane Maria Valentim Willi; Norma Vollmer Labarthe; Luiz Ney d'Escoffier; Jonimar Pereira Paiva; Marcia Gonçalves Nobre de Miranda; Flavya Mendes-de-Almeida; Tânia Zaverucha do Valle
Journal:  BMC Res Notes       Date:  2018-02-23

Review 6.  Drug resistance in liver flukes.

Authors:  I Fairweather; G P Brennan; R E B Hanna; M W Robinson; P J Skuce
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2020-01-10       Impact factor: 4.077

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.